Targovax: First patient dosed with TG01 in the USA
· The first patient has been dosed with TG01 at The University of Kansas Cancer Center · In this study, mutant RAS vaccine TG01 is being tested in in pancreatic cancer in combination with PD-1 checkpoint inhibitor balstilimab from collaboration partner AgenusOslo, Norway, 14 March 2023 - Targovax ASA (OSE: TRVX), today announces that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way